As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
The Microbiota-Gut Brain Axis
We are currently accepting submissions to a new cross-journal series, The Microbiota-Gut-Brain Axis.
In partnership with twelve other BMC journals, this series will bring together human and animal studies covering all aspects of the axis' role in health and disease, including Alzheimer's.
Announcing the launch of In Review
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Alzheimer's blogs from BMC
Annual Journal Metrics
56 days to first decision for reviewed manuscripts only
32 days to first decision for all manuscripts
128 days from submission to acceptance
25 days from acceptance to publication
1,172 Altmetric mentions